Physician

John David Purviance, M.D.

According to 2025 Medicare claims, John Purviance, M.D. (NPI: 1437279692) practices radiation oncology in the Casper, WY market, with the plurality of this provider's patient population coming from Natrona, WY. This provider's primary affiliated billing organization is ROCKY MOUNTAIN ONCOLOGY CENTER, LLC (NPI: 1003862723; TIN: 731684200) and primary practice location at 82609-4293.

Purviance's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 937 traditional Medicare patients, billed 35,924 HCPCS/CPT codes, and received $2,759,378 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 665 prescription claims across 185 beneficiaries totaling $17,718 in drug costs, led by Tamsulosin Hcl (Tamsulosin Hcl). 2022 DME data shows 13 claims. Open Payments data shows 48 records totaling $904. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,862,066 to $2,759,378. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $13,439 and ending at $17,718. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	679	26,835	$1,862,066
2016	720	29,918	$1,931,828
2017	717	26,288	$1,531,668
2018	748	33,391	$2,000,319
2019	799	33,319	$2,307,325
2020	844	34,864	$2,735,160
2021	842	28,057	$2,003,707
2022	940	44,000	$2,582,270
2023	1,049	40,898	$2,659,576
2024	937	35,924	$2,759,378

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	122	397	$13,439
2016	131	487	$12,804
2017	125	466	$12,303
2018	158	624	$22,113
2019	166	574	$17,471
2020	174	542	$12,794
2021	177	505	$12,281
2022	178	546	$16,699
2023	186	653	$44,121
2024	185	665	$17,718

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	22	$3,522
2017	N/R	26	$3,198
2018	N/R	12	$1,255
2019	N/R	14	$1,732
2020	N/R	26	$2,793
2021	N/R	N/R	N/R
2022	N/R	13	$1,909
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	332	829	$692
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	257	354	$300
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	337	445	$98
77300	Calculation of radiation therapy dose	168	1,664	$28
36415	Insertion of needle into vein for collection of blood sample	204	288	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tamsulosin Hcl	Tamsulosin Hcl	272	16,748	$6,554
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	189	$531
Levothyroxine Sodium	Levothyroxine Sodium	42	2,929	$443
Morphine Sulfate Er	Morphine Sulfate	12	360	$328
Pregabalin	Pregabalin	15	600	$310

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	48	$904	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John David Purviance, M.D.?

Tedicare shows public-source Medicare data for John David Purviance, M.D. (NPI 1437279692), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John David Purviance, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John David Purviance, M.D.?

John David Purviance, M.D. is linked to ROCKY MOUNTAIN ONCOLOGY CENTER, LLC (billing NPI 1003862723) in the available physician profile data.

Does John David Purviance, M.D. have Open Payments data?

John David Purviance, M.D. has 48 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.